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SHORT COMMUNICATION
Accumulation of natural killer cells after hepatic artery embolisation in
the midgut carcinoid syndrome
B Wingberg', H Ahiman', U Tyln2, 0 Nilsson3, S Hermodsson4 and K Hellstrand4
Departments of 'Surgery, 2Radiology, 3Pathology and 'Clincal Virology, Sahlgrenska Hospital, Gothenburg, Sweden.
Eleven patients with midgut carcinoid tmour disca were subjected to hepatic artery
embolisation. In six patients, lymphocytosis with a predominance of NK cells occurred and the cytotoxic
activity of isolated lymplocytes incrased. A relation between NK cell accumulation and s t
radiological and biochemical response was observed, and it is sugsted that anti-tumour mechaniss other
than i emia may contribute to the therapeutic response in these patients.
Keyword= NK cells, carcinoid tumours; hepatic artery embo}isation
Hepatic artery embolisation is a well-documented method in
the treatment of patients with disseminated midgut caranoid
tumours. After embolisation, an increased urinary excretion
of 5-hydroxyindoleacetic acid (5-HIAA) indicates tumour cell
necrosis with subsequent release of serotonin (5-Hi) (Ahl-
man et al., 1991). In previous studies, embo}isation therapy
has been instituted to obtain symptom relief at a late stage of
the disease and thus added little to survival (Coupe et al.,
1989). At our unit all patients with bilobar hepatic metas-
tases during the last 6 years have undergone embolisation
subsequent to prinary surgery, with octreotide as adjuvant
therapy (200 jg s.c. daily). In a follow-up study of the
therapeutic resonse it was shown that the patients could be
divided into two groups: (I) responders with more than 50%
tumour reduction, evaluated by computeried tomography
(CT) 3 months post embolisation, and a pronounced reduc-
tion in 5-HAA excretion (80 ± 3%); (II) non-responders
with less than 50% tumour reduction, or progressive disease,
and a moderate 5-HAA reduction (28 ± 12%). The first
group of patients had a therapeutic response of much longer
duration (Wingberg et al., 1993). The therapeutic effect has
been attributed to ischaemic damage to tumour cells. How-
ever, in three patients we observed bilateral tumour regres-
sion after unilateral embolisation, which focused our interest
on potential activation of systemic anti-tumour
mechanisms.
Natural killer (NK) cells are a subset of lymphocytes that
kill tumour cells in a non-MHC-restriced fashion (Trinhieri,
1989). NK cells are non-T (CD3-) lymphocytes that express
CD56, a surface glycoprotein which represents an isoform of
the neural cell adhesion protein (N-CAM), and CD16, a
low-affinity cell-surface receptor for the Fc part of IgG.
Functions of NK cells are positively regulated by 5-HT, the
main prodt of midgut carcinoid tumour cells. 5-HT
effectively augments the cytotoxic, proliferative and
lymphokine-producing activities of NK cells by reversing a
cell contact-dependent, suppressive signal from phagocytes
(Hellstrand and Hermodsson, 1987, 1993). Against this back-
ground, we chose to monitor the fiequency of lymphocytes
with NK cell phenotype (CD3-/56+) and NK cell cytotox-
icity against susceptible tumour target cells in the peripheral
venous blood of patients with hepatic carcinoid metastases
subjected to hepatic artery emboisation.
MNaterial amd
Eleven patients with hepatic metastases of midgut carcinoid
tumours and markedly elevated urinary 5-HIAA excretion
(759±195gamol24h-', reference vahle <50imol24h-1)
were treated with hepatic artery embolisation. Since the
patients served as their own controls, venous blood was
drawn from a central venous catheter immediately before and
15 min after unilateral embolisation. Mononuclear cells
(MNCs) were isolated using Ficoll-Hypaque density gra-
dient centrifugation (Hellstrand and Hermodsson, 1993). The
NK cell-mediated cytotoxicity of MNC was analysed using
K562 erythrokeukaemic target cells as described in detail
previously (Helltrand and Hermodsson, 1987). Three MNC
to target cell (E/i) ratios were used and results plottedLThe
percentage of killed tumour cells (per cent cell lysis) was
calclated at an E/T ratio of 20:1. The frequency of lympho-
cytes with T- and NK-cell phenotype was analysed by use of
flow cytometry (FACSort, Becton Dickinson, Stockholm,
Sweden) after stining of lymphocyte or whole-blood speci-
mens with fluorescin isothiocyanate (FITC)-conjugted anti-
CD3 and PE-conjugated anti-CD56. In some patients the
frequency of CD56+ NK cells carrying the CD16 antigen was
analysed using FITC-conjugated anti-CD16. All patient sam-
ples were analysed using fresh cells imeiately after each
embolisation and without knowledge of the clinical response
status. Clinical responses were evahlated biochemically and
radiologically (CT) at 3 months post emboisation. Patients
with more than 50% tumour reduction, as evaluated by CT,
and more than 50% reduction of the urinary 5-HIAA excre-
tion (mol 24 h-') were classifd as responders.
ResdAs
In 6 of the 11 patients (54%) a marked lymphocytosis occur-
red within 15 min after the onset of embolisation. Analyses
of the frequency of T cells (CD3+/56-), NK cells (CD3-/
56+), null cells (CD3-/56-) and non-MHC-restricted T cells
(CD3+/56+) by use of flow cytometry revealed that the pre-
dominant accumulating cell type was NK cells. The vast
majority of these cels (85%) also arried the CD16 antigen
(Figure 1). Accumulating NK cells were almost exclusively of
the CD56&M phenotype. In most patients the proportion of
CD3+/56+ cells ('non-MHC-restricted T cells') was less than
5% of gated lymphocytes and did not chang after emboisa-
tion. The cytotoxic activity of isolated MNCs against NK
cell-suscePtible target cells was augmented in paralle with the
increased number of NK cells (Figure 2). The cytotoxicity in
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Figre 1 Effect of hepatic artery embolisation on NK-cell
markers in peripheral blood lymphocytes. CeUls from whole-blood
specimens were obtained from peripheral venous blood before
(left) and after embolisation (right). The cells were stained with
FITC-conjugated anti-CD16 and PE-conjugated CD56 (upper
two maps) or FITC-conjugated anti-CD3 and PE-conjugated
anti-CD56 (lower two maps) and analysed by flow cytometry.
Data show the proportion of gated lymphocytes with each
phenotype in a representative patient with tumour regression.
The x- and Y-axes are 4-decade log scales. This patient had an
increase of NK cells from 18.0 to 48.0% and in NK-cell cytotox-
icity from 22.1 to 60.5 (per cent lysis). Urinary excretion of
5-HIAA decreased by 75% and the tumour reduction on CT
exceeded 50%.
relation to number of NK cells was not changed after embol-
isation (data not shown), indicating that the NK cells re-
cruited after embolisation were functionally similar to the
pre-existing population in peripheral blood.
When evaluated biochemically and radiologically 3 months
post embolisation, six patients were classified as responders
and five as non-responders. The accumulation of NK cells
and the clinical response seemed to be related, except in one
patient with rapidly progressive extrahepatic disease (Figure
2). Interestingly, in contrast to all other patients, CD3+/56+
cells accumulated (9.0-25.8%) in this patient in parallel with
the accumulation of NK cells (14.5-31.3%). The mean NK
cell cytotoxicity (per cent cell lysis) before and after embol-
isation among the responders was 17.7% and 40.3% respec-
tively. The mean frequency of lymphocytes with NK cell
phenotype increased from 13.6% to 32.2%. Among the non-
responders the NK cell cytotoxicity, before and after
embolisation, was 15.0% and 20.8% and the corresponding
frequency of NK cells was 12.3 and 16.8% respectively.
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Fugwe 2 Effects of hepatic artery embolisation on NK cells. The
left panel shows the frequency (%) of NK cells (with CD3- 56'
phenotype) in peripheral blood lymphocytes before and after
embolisation (cf. Figure 1). The nrght panel shows NK-cell cyto-
toxicity of mononuclear cells from individual patients against
K562 target cells, expressed as the percentage of killed tumour
cells at an MNC to target cell ratio of 20:1. Filled dots represent
patients with objective clinical response, evaluated biochemically
and radiologically at 3 months post embolisation.
Discussion
Previous studies have shown a decreased number and a
reduced cytotoxicity of NK cells after surgery with a second
reduction in NK-cell activity after subsequent chemotherapy
(Lukomska et al., 1983; Brenner and Margolese, 1991; Pol-
lock et al., 1991). The present study demonstrates a remark-
able accumulation of NK cells in peripheral blood after
hepatic artery embolisation and suggests that immunological
anti-tumour mechanisms may be initiated by embolisation in
certain patients with the midgut carcinoid syndrome. An
immunological response rate of 54% is in accordance with
the findings at earlier clinical follow-up studies in which half
of the patients had a pronounced tumour reduction of long
duration. The immunological response may be amplified by
the release of tumour cell products, e.g. 5-HT, interleukin 2
(IL-2) and tachykinins. In two patients studied, the number
of NK cells remained elevated when analysed 3-10 days post
embolisation. It cannot be excluded that two unrelated
phenomena are observed, i.e. one group of patients has an
anti-tumour response and in these patients NK cells are
mobilised perhaps from stores within the liver. However, the
clinical follow-up indicates that the immunological response
may serve as an early marker of the therapeutic effect. The
mere presence of the demonstrated NK-cell accumulation
may contradict the immediate use of chemotherapy following
embolisation or a combined treatment strategy, e.g.
chemoembolisation.
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